http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BG-60506-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e7af8847969b90f35bb949bd09f73f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-22 |
| filingDate | 1992-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_627493abec5f24368acf82d56bb9ea80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2674f2cb42872b44ffdb91fd3d5c099 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd6e650f829eb34efd686214edaec107 |
| publicationDate | 1995-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BG-60506-B2 |
| titleOfInvention | HUMAN RECOMBINANT INTERLINE-2 MUTEINS |
| abstract | Muteins are used in the diagnosis and treatment of viral, bacterial, protozoal and fungal infections. They enhance cell mediated cytotoxicity and help restore immune functions, including in acquired immune deficiency conditions. Muteins are produced by bacterial expression of mutant genes encoding muteins synthesized by genes for parent proteins by oligonucleotide directed mutagenesis. Typical of muteins of biologically active proteins such as ifn and il-2 is that cysteine residues that are not essential for biological incitement are released or replaced with other amino acids, thereby eliminating sites for formation of disulfide bond in the molecule. |
| priorityDate | 1989-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 197.